Cargando…

Bariatric Surgery Leads to a Reduction in Antibodies to Apolipoprotein A-1: a Prospective Cohort Study

PURPOSE: Autoantibodies against apolipoprotein A-1 have been associated with cardiovascular disease, poorer CV outcomes and all-cause mortality in obese individuals. The impact of bariatric surgery (BS) on the presence of circulating anti-apoA-1 IgG antibodies is unknown. This study aimed to determi...

Descripción completa

Detalles Bibliográficos
Autores principales: Adam, Safwaan, Ho, Jan H., Liu, Yifen, Siahmansur, Tarza, Iqbal, Zohaib, Pagano, Sabrina, Azmi, Shazli, Dhage, Shaishav S., Donn, Rachelle, Ammori, Basil J., Syed, Akheel A., Durrington, Paul N., Malik, Rayaz A., Vuilleumier, Nicolas, Soran, Handrean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794910/
https://www.ncbi.nlm.nih.gov/pubmed/34888742
http://dx.doi.org/10.1007/s11695-021-05738-7
_version_ 1784640930542780416
author Adam, Safwaan
Ho, Jan H.
Liu, Yifen
Siahmansur, Tarza
Iqbal, Zohaib
Pagano, Sabrina
Azmi, Shazli
Dhage, Shaishav S.
Donn, Rachelle
Ammori, Basil J.
Syed, Akheel A.
Durrington, Paul N.
Malik, Rayaz A.
Vuilleumier, Nicolas
Soran, Handrean
author_facet Adam, Safwaan
Ho, Jan H.
Liu, Yifen
Siahmansur, Tarza
Iqbal, Zohaib
Pagano, Sabrina
Azmi, Shazli
Dhage, Shaishav S.
Donn, Rachelle
Ammori, Basil J.
Syed, Akheel A.
Durrington, Paul N.
Malik, Rayaz A.
Vuilleumier, Nicolas
Soran, Handrean
author_sort Adam, Safwaan
collection PubMed
description PURPOSE: Autoantibodies against apolipoprotein A-1 have been associated with cardiovascular disease, poorer CV outcomes and all-cause mortality in obese individuals. The impact of bariatric surgery (BS) on the presence of circulating anti-apoA-1 IgG antibodies is unknown. This study aimed to determine the effect of bariatric surgery on auto-antibodies titres against Apolipoprotein A-1 (anti-apoA-1 IgG), looking for changes associated with lipid parameters, insulin resistance, inflammatory profile and percentage of excess body mass index loss (%EBMIL). MATERIALS AND METHODS: We assessed 55 patients (40 women) before, 6 and 12 months post-operatively. Baseline and post-operative clinical history and measurements of body mass index (BMI), serum cholesterol, triglycerides, high- and low-density lipoprotein cholesterol (HDL-C and LDL-C), apoA-1, highly sensitive C-reactive protein (hsCRP), fasting glucose (FG), glycated haemoglobin (HbA1c) and HOMA-IR were taken at each point. Human anti-apoA-1 IgG were measured by ELISA. RESULTS: The mean age of participants was 50 years. BS significantly improved BMI, %EBMIL triglycerides, HDL-C, apoA-1, hsCRP, HBA1c, FG and HOMA-IR. Baseline anti-apoA-1 IgG seropositivity was 25% and was associated with lower apoA-1 and higher hsCRP levels. One year after BS, anti-apoA-1 IgG seropositivity decreased to 15% (p = 0.007) and median anti-apoA-1 IgG values decreased from 0.70 (0.56–0.84) to 0.47 (0.37–0.61) AU (p < 0.001). Post-operative anti-apoA-1 IgG levels were significantly associated with a decreased post-surgical %EBMIL at 1 year. CONCLUSION: Bariatric surgery results in significant reduction in anti-apoA-1 IgG levels, which may adversely influence weight loss. The exact mechanisms underpinning these results are elusive and require further study before defining any clinical recommendations. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-8794910
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-87949102022-02-02 Bariatric Surgery Leads to a Reduction in Antibodies to Apolipoprotein A-1: a Prospective Cohort Study Adam, Safwaan Ho, Jan H. Liu, Yifen Siahmansur, Tarza Iqbal, Zohaib Pagano, Sabrina Azmi, Shazli Dhage, Shaishav S. Donn, Rachelle Ammori, Basil J. Syed, Akheel A. Durrington, Paul N. Malik, Rayaz A. Vuilleumier, Nicolas Soran, Handrean Obes Surg Original Contributions PURPOSE: Autoantibodies against apolipoprotein A-1 have been associated with cardiovascular disease, poorer CV outcomes and all-cause mortality in obese individuals. The impact of bariatric surgery (BS) on the presence of circulating anti-apoA-1 IgG antibodies is unknown. This study aimed to determine the effect of bariatric surgery on auto-antibodies titres against Apolipoprotein A-1 (anti-apoA-1 IgG), looking for changes associated with lipid parameters, insulin resistance, inflammatory profile and percentage of excess body mass index loss (%EBMIL). MATERIALS AND METHODS: We assessed 55 patients (40 women) before, 6 and 12 months post-operatively. Baseline and post-operative clinical history and measurements of body mass index (BMI), serum cholesterol, triglycerides, high- and low-density lipoprotein cholesterol (HDL-C and LDL-C), apoA-1, highly sensitive C-reactive protein (hsCRP), fasting glucose (FG), glycated haemoglobin (HbA1c) and HOMA-IR were taken at each point. Human anti-apoA-1 IgG were measured by ELISA. RESULTS: The mean age of participants was 50 years. BS significantly improved BMI, %EBMIL triglycerides, HDL-C, apoA-1, hsCRP, HBA1c, FG and HOMA-IR. Baseline anti-apoA-1 IgG seropositivity was 25% and was associated with lower apoA-1 and higher hsCRP levels. One year after BS, anti-apoA-1 IgG seropositivity decreased to 15% (p = 0.007) and median anti-apoA-1 IgG values decreased from 0.70 (0.56–0.84) to 0.47 (0.37–0.61) AU (p < 0.001). Post-operative anti-apoA-1 IgG levels were significantly associated with a decreased post-surgical %EBMIL at 1 year. CONCLUSION: Bariatric surgery results in significant reduction in anti-apoA-1 IgG levels, which may adversely influence weight loss. The exact mechanisms underpinning these results are elusive and require further study before defining any clinical recommendations. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2021-12-09 2022 /pmc/articles/PMC8794910/ /pubmed/34888742 http://dx.doi.org/10.1007/s11695-021-05738-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Contributions
Adam, Safwaan
Ho, Jan H.
Liu, Yifen
Siahmansur, Tarza
Iqbal, Zohaib
Pagano, Sabrina
Azmi, Shazli
Dhage, Shaishav S.
Donn, Rachelle
Ammori, Basil J.
Syed, Akheel A.
Durrington, Paul N.
Malik, Rayaz A.
Vuilleumier, Nicolas
Soran, Handrean
Bariatric Surgery Leads to a Reduction in Antibodies to Apolipoprotein A-1: a Prospective Cohort Study
title Bariatric Surgery Leads to a Reduction in Antibodies to Apolipoprotein A-1: a Prospective Cohort Study
title_full Bariatric Surgery Leads to a Reduction in Antibodies to Apolipoprotein A-1: a Prospective Cohort Study
title_fullStr Bariatric Surgery Leads to a Reduction in Antibodies to Apolipoprotein A-1: a Prospective Cohort Study
title_full_unstemmed Bariatric Surgery Leads to a Reduction in Antibodies to Apolipoprotein A-1: a Prospective Cohort Study
title_short Bariatric Surgery Leads to a Reduction in Antibodies to Apolipoprotein A-1: a Prospective Cohort Study
title_sort bariatric surgery leads to a reduction in antibodies to apolipoprotein a-1: a prospective cohort study
topic Original Contributions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794910/
https://www.ncbi.nlm.nih.gov/pubmed/34888742
http://dx.doi.org/10.1007/s11695-021-05738-7
work_keys_str_mv AT adamsafwaan bariatricsurgeryleadstoareductioninantibodiestoapolipoproteina1aprospectivecohortstudy
AT hojanh bariatricsurgeryleadstoareductioninantibodiestoapolipoproteina1aprospectivecohortstudy
AT liuyifen bariatricsurgeryleadstoareductioninantibodiestoapolipoproteina1aprospectivecohortstudy
AT siahmansurtarza bariatricsurgeryleadstoareductioninantibodiestoapolipoproteina1aprospectivecohortstudy
AT iqbalzohaib bariatricsurgeryleadstoareductioninantibodiestoapolipoproteina1aprospectivecohortstudy
AT paganosabrina bariatricsurgeryleadstoareductioninantibodiestoapolipoproteina1aprospectivecohortstudy
AT azmishazli bariatricsurgeryleadstoareductioninantibodiestoapolipoproteina1aprospectivecohortstudy
AT dhageshaishavs bariatricsurgeryleadstoareductioninantibodiestoapolipoproteina1aprospectivecohortstudy
AT donnrachelle bariatricsurgeryleadstoareductioninantibodiestoapolipoproteina1aprospectivecohortstudy
AT ammoribasilj bariatricsurgeryleadstoareductioninantibodiestoapolipoproteina1aprospectivecohortstudy
AT syedakheela bariatricsurgeryleadstoareductioninantibodiestoapolipoproteina1aprospectivecohortstudy
AT durringtonpauln bariatricsurgeryleadstoareductioninantibodiestoapolipoproteina1aprospectivecohortstudy
AT malikrayaza bariatricsurgeryleadstoareductioninantibodiestoapolipoproteina1aprospectivecohortstudy
AT vuilleumiernicolas bariatricsurgeryleadstoareductioninantibodiestoapolipoproteina1aprospectivecohortstudy
AT soranhandrean bariatricsurgeryleadstoareductioninantibodiestoapolipoproteina1aprospectivecohortstudy